Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Efficacy of trastuzumab-emtansine in breast cancer patients prior treated with pertuzumab
Örebro University, School of Medical Sciences.
2019 (English)Independent thesis Basic level (degree of Bachelor), 10 credits / 15 HE creditsStudent thesis
Abstract [en]

Background:T-DM1 is preferred treatment option as2ndline treatmentinpatients with metastatic HER2-positive breast cancer after progression in trastuzumab-based 1stline treatment. When T-DM1 became the preferred treatment strategy as2ndline therapy,the1stline treatment did not include pertuzumabwhich is currently standard of care. Therefore, there is lack ofknowledge aboutT-DM1 response in patients who received prior pertuzumab.

Aim:To study the efficacyof T-DM1 inpatients prior treated with pertuzumab as a 1stline treatment compared to patients without prior pertuzumab use.

Patients and methods:We performed aretrospective cohort studyincluding all patientswith HER2 positive metastatic breast cancertreated with T-DM1 at 3 Hospitals (Eskilstuna, Uppsala, Örebro) between 2014 and 2017. This study included 35 patients.

Results:Objective response rate (complete response or partial response), stable disease and progressive disease was50%,33.3% and16.7%, respectivelyin patients with prior pertuzumab treatmentwhereas the rates inno priorpertuzumabpatients were41.2%, 29.4% and 29.4%, respectively.No significantdifference intime to progression (TTP) was observed between prior pertuzumaband noprior pertuzumab groups (log-rank test with p-value=0.227). TTP was comparable between patients who received T-DM1 as 2ndline and patients who received T-DM1 as≥ 3rdlinetreatment(log-rank test with p-value=0.601).

Conclusion:Prior pertuzumab use didnotseem to jeopardize T-DM1 efficacy in breast cancer patients with HER2-positive metastatic breast cancer. T-DM1 is an effective treatment strategy irrespective of theline of treatment.

Place, publisher, year, edition, pages
2019.
National Category
Medical and Health Sciences
Identifiers
URN: urn:nbn:se:oru:diva-78031OAI: oai:DiVA.org:oru-78031DiVA, id: diva2:1372426
Subject / course
Medicine
Examiners
Available from: 2019-11-23 Created: 2019-11-23 Last updated: 2019-11-23Bibliographically approved

Open Access in DiVA

fulltext(355 kB)3 downloads
File information
File name FULLTEXT01.pdfFile size 355 kBChecksum SHA-512
b0e7448be528561eaf2c48cd5d51271ced1aea9a946f1df6304c203f3d4fa3ed00f1118ff9cffe5aa8dd96d117fdbae52914e6f255b32aabc92ab3ef14371032
Type fulltextMimetype application/pdf

By organisation
School of Medical Sciences
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
Total: 3 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

urn-nbn

Altmetric score

urn-nbn
Total: 2 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf